BBT002 Safety and Effects in COPD and Healthy Volunteers
BBT002
+ Placebo
Chronic Disease+5
+ Lung Diseases
+ Lung Diseases, Obstructive
Treatment Study
Summary
Study start date: September 5, 2025
Actual date on which the first participant was enrolled.This study explores a new treatment called BBT002, aiming to see how safe it is and how it behaves in the body. The research involves both healthy volunteers and individuals with Chronic Obstructive Pulmonary Disease (COPD), a condition that makes it hard to breathe. Understanding the effects of BBT002 could lead to better treatments for those suffering from COPD, potentially easing their symptoms and improving their quality of life. The study is significant because it addresses the need for more effective COPD treatments. Participants in the study will receive BBT002 in two parts. In the first part, healthy volunteers will take a single dose, while in the second part, those with COPD will receive two repeated doses. Researchers will monitor participants closely, looking for any side effects and measuring changes in heart activity, blood tests, and overall health through physical exams. The study aims to gather detailed information on any adverse events and how the body responds to BBT002, including changes in vital signs like blood pressure and heart rate.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.68 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 75 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria:( A\&B) 1. Age of 18-65 years (HVs), 35-75 years (patients) 2. Body mass index between 18-32 kg/m², capped at 120 kg 3. Negative pregnancy tests for women of childbearing potential 4. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit 5. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers 6. Adequate contraception use (for men and women of childbearing potential) 7. No clinically significant abnormalities or history of relevant diseases Key Inclusion Criteria (Part B only) 1. Documented history of COPD with a post-bronchodilator FEV1/FVC \< 0.70 2. FEV1 ≥ 50% and FEV1\<80% predicted at screening. Exclusion Criteria:( part A \& B) 1. Positive viral serology for human immunodeficiency virus (HlV), hepatitis C virus (HCV), or hepatitis B (HBV) 2. Immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections 3. History of major metabolic, dermatological, liver, kidney, hematological or other significant disorders 4. Clinically relevant abnormal lab results, including low blood counts, liver enzymes, or abnormal kidney function 5. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1 6. Abnormal Electrocardiogram(ECG) findings 7. History of drug/alcohol abuse in the past 2 years 8. History of severe allergic reactions or hypersensitivity Key Exclusion Criteria for (Part B only) 1. Current diagnosis of other significant pulmonary disease 2. Significant or unstable cardiovascular diseases 3. Recent clinically significant infection 4. Inability to perform spirometry
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.4 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
PlaceboGroup IV
PlaceboStudy Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 11 locations
The Second Hospital of Anhui Medical Univesity
Hefei, ChinaOpen The Second Hospital of Anhui Medical Univesity in Google MapsThe third affiliated hosptial of Guangzhou Medical University
Guangzhou, ChinaThe First Affiliated Hospital of Guangdong Medical University
Guangzhou, ChinaJiangmen Central Hospital
Jiangmen, China